Abstract
Although H-1 parvovirus is used as an antitumor agent, not much is known about the relationship between its specific tropism and oncolytic activity. We hypothesize that VP2, a major capsid protein of H-1 virus, determines H-1-specific tropism. To assess this, we constructed chimeric H-1 viruses expressing Kilham rat virus (KRV) capsid proteins, in their complete or partial forms. Chimeric H-1 viruses (CH1, CH2 and CH3) containing the whole KRV VP2 domain could not induce cytolysis in HeLa, A549 and Panc-1 cells. However, the other chimeric H-1 viruses (CH4 and CH5) expressing a partial KRV VP2 domain induced cytolysis. Additionally, the significant cytopathic effect caused by CH4 and CH5 infection in HeLa cells resulted from preferential viral amplification via DNA replication, RNA transcription and protein synthesis. Modeling of VP2 capsid protein showed that two variable regions (VRs) (VR0 and VR2) of H-1 VP2 protein protrude outward, because of the insertion of extra amino-acid residues, as compared with those of KRV VP2 protein. This might explain the precedence of H-1 VP2 protein over KRV in determining oncolytic activity in human cancer cells. Taking these results together, we propose that the VP2 protein of oncolytic H-1 parvovirus determines its specific tropism in human cancer cells.
Similar content being viewed by others
Introduction
Virotherapy has been used as an alternative strategy for the treatment of cancer owing to the rise in the number of cancer cells resistant to chemotherapeutic drugs or radiation therapy.1, 2 Virotherapy uses viruses that preferentially replicate in tumor cells.3 For example, some viruses used in the clinical treatment of cancer include the H-1 virus,4 reovirus5, 6 and vaccinia virus.7
H-1 parvovirus is a small, single-stranded DNA virus that lacks an envelope, and expresses two major nonstructural proteins (NS1 and NS2) and two capsid structural proteins (VP1 and VP2).8 VP1 protein is a minor capsid protein, which consists of a unique N-terminal residue and VP2 capsid protein. The VP2 major capsid protein is required for capsid assembly.9, 10 Although rodent cells are the natural host for the H-1 virus, they can also infect transformed human cells.11, 12 In permissive cells, the H-1 virus replicates during the S phase of the cell cycle and undergoes lytic cycle, where the main replication and assembly steps occur in the nucleus, typically leading to apoptotic and lysosome-mediated cell death.13, 14 H-1 virus is considered to be oncotropic, efficiently infecting human tumor cells such as melanoma,15 hepatoma16 and glioblastoma,17 as well as cancerous colon and gastric tissues.18, 19
Kilham rat virus (KRV), belonging to the same Parvoviridae family as the H-1 virus, replicates in its natural host rodent cells.20 Surprisingly, KRV induces autoimmune type I diabetes in diabetes-resistant biobreeding rats.21, 22 Despite its many similarities to KRV, H-1 virus does not induce autoimmune diabetes in the same rodent model.23
In this study, we found that H-1 virus induced cytopathic effects on HeLa cells but KRV did not. We hypothesized that the H-1 viral capsid protein determines the susceptibility of human cancer cells to H-1 infection. To test this hypothesis, we constructed chimeric H-1 viruses expressing various forms of the KRV capsid protein. We have discovered that VP2, a major capsid domain of H-1 virus, is responsible for the ability of the virus to infect human cancer cells.
Materials and methods
Cell cultures and transfection
Normal rat kidney (NRK) cells purchased from ATCC (Manassas, VA, USA), HeLa, A549 (human lung carcinoma cell line) and Panc-1 (human pancreas/duct carcinoma line) cells were cultured in Dulbecco’s modified Eagle's medium (DMEM; Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin (Gibco) at 37 °C in a humidified atmosphere of 5% CO2. The cells were plated at a frequency of 5 × 105 cells in a 60 mm culture plate 24 h before transfection. These were then transfected with 2 μg of DNA using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
Immunoblotting
Cells were harvested and lysed with lysis buffer (150 mm NaCl, 1% NP-40, 50 mm Tris-HCl (pH 7.5)) containing 0.1 mm Na2VO3, 1 mm NaF and protease inhibitors (Sigma-Aldrich, St Louis, MO, USA). Proteins from cell lysates were resolved by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The resolved proteins were transferred to nitrocellulose membranes. Primary antibodies at 1:1000 dilutions and secondary antibodies conjugated with horseradish peroxidase were used at dilutions of 1:2000 in 5% nonfat dry milk. After the final wash, the membranes were examined by an enhanced chemiluminescence assay, using the ImageQuant LAS 4000 Mini (GE Healthcare, Buckinghamshire, UK).
Construction of chimeric H-1 viruses
NRK cells infected with KRV were recovered 24 h after infection, and KRV replicative form DNA was isolated as described previously.24 The infectious H-1 virus DNA clone (pSR19)25 was used as a backbone vector for the construction of chimeric H-1 viruses. To insert KRV genomic DNA into the pSR19 vector, KRV replicative form DNA was digested with EcoRI and HpaI. A new chimeric H-1 vector was constructed through ligation and transformation. pCH2 vector was generated by replacing the KRV replicative form DNA in pSR19, with one digested with StuI and HpaI. Other chimeric H-1 virus vectors were generated by digestion at restriction enzyme sites common to both KRV and H-1 viral genomic DNA, as seen in Figures 1b. For the production of chimeric H-1 viruses, each chimeric H-1 vector was transfected into NRK cells, and the cells harvested 7 days after transfection. The cell supernatant was inoculated to fresh NRK cells for amplification of chimeric H-1 viruses. Virus titers were measured as 50% tissue culture infective dose per ml (TCID50 per ml).
Sequencing of KRV genomic DNA
KRV NS1 and NS2 genes were cloned into the pCR2 vector based on the published H-1 viral genomic sequence. The sequencing was conducted at Macrogen (Daejeon, Korea), and 1-Topo vector (Invitrogen) was used for the cloning of products. pCH1 vector, which includes KRV replicative form DNA spanning the EcoRI and HpaI sites, was used for sequencing of KRV VP1 and VP2 genes. The sequenced KRV NS1, NS2, VP1 and VP2 genes were deposited at GenBank (accession nos. KM999994–999997).
Real-time quantitative PCR
H-1, KRV and chimeric virus genomic DNA were isolated from infected HeLa cells using the QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s recommendations. Total RNA was isolated from HeLa cells infected with H-1, KRV or chimeric viruses (CH1–5), and the cDNAs were synthesized using the QuantiTect Probe Reverse Transcriptase-PCR (RT-PCR) Kit (Qiagen) according to the protocols provided by the manufacturer. The reaction mix for all reactions were composed of 10 μl of 2 × QuantiTec Probe RT-PCR Master Mix, NS1 forward and reverse primers (each at a final concentration 0.4 μm), probe and template DNA. The primers sequences for NS1 were: forward, 5′-ACCGAAACAAACCAACCAG-3' and reverse, 5′-TCCCAGTAGAAACACCAATCC-3′). The probe sequence used was (5FAM)-GGAATCGCTAATGCTAGAGTTGAGCG-(3BHQ1); all three were designed from the NS1 genome. The PCR reaction conditions were as follows: a denaturing step at 95 °C for 15 min, followed by 30 cycles of denaturation at 95 °C for 60 s, and annealing at 58 °C for 30 s. A standard curve was generated for the linearized pSR19 vector carrying the whole H-1 genome. This curve was used for the quantitative measurement of viral transcript. All reactions were conducted on the CFX96 Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA) and the data were analyzed using the CFX Manager Software version 3.1 (Bio-Rad).
Production of polyclonal H-1 antibodies
The NRK cell monolayers were infected with wild-type H-1 virus until a cytopathic effect was observed (~60% cell lysis). The cells were harvested by low-speed centrifugation at 500 g at 10 °C for 15 min. The virus was released from the frozen cells by three rapid freeze–thaw cycles, and purified by two rounds of sucrose discontinuous gradient separation (first round: 5–50%; second round: 10–40%) at 72 000 g (SW28 rotor; Beckman Coulter, Indianapolis, IN, USA) and 10 °C for 12 h. The purity and integrity of the virus was monitored by 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis with Coomassie Blue staining. The purified, inactivated H-1 virus was injected subcutaneously into rabbits (200 μg per injection) with associated adjuvants at 2-week intervals, and the sera produced were isolated to obtain a polyclonal H-1 antibody, which mainly recognizes the H-1 VP2 capsid protein.
Modeling of VP2 capsid protein from KRV and H-1 virus
A model of the KRV VP2 (GenBank accession no. 999997) protein was built with SWISS-MODEL,26 using the H-1 parvovirus VP2 (PDB ID: 4G0R)8 protein as a template. The template structure was selected based on amino-acid sequence identity (79% sequence identity) using the BLAST (basic local alignment search tool) search, and obtained from Protein Data Bank (http://www.rcsb.org) with the highest resolution. Molecular graphics modeling and analyses were performed with the UCSF Chimera package27.
Statistical analysis
Data were presented as mean±s.e.m. The Student’s t-test was used for statistical analysis, with P-values <0.05 being defined as significant.
Results
Comparison of genomic DNA and amino-acid sequences between KRV and H-1 virus
Although it is well known that KRV and H-1 viruses are similar, their infectivity patterns have not yet been reported in detail. First, we sequenced the genomic DNA of KRV purchased from ATCC, and compared its sequence with that of the H-1 virus. As seen in Table 1, NS1 and NS2 proteins from the H-1 and KRV viruses shared over 99% nucleotide and amino-acid sequence homology. Furthermore, VP1 genes of the H-1 and KRV viruses showed 86.2% nucleotide sequence homology and 78.8% amino-acid sequence homology. VP2 genes from the H-1 and KRV viruses demonstrated 83.3% nucleotide sequence homology and 73.4% amino-acid sequence homology. This result indicates that NS1 and NS2 genes have an essential role in the common elements of the KRV and H-1 viral life cycles. This also indicated that the ~20% difference in amino-acid sequence of the viral capsid proteins (VP1 and VP2) allows for unique properties in their individual life cycles.
H-1-specific tropism determined by H-1 VP2 capsid protein overwhelms the KRV-specific tropism that depends on the KRV VP2 capsid protein
Other studies have suggested that subtle differences between the capsid proteins of canine parvovirus (CPV) and feline leukopenia virus (FPV), or those of lymphotropic and fibrotropic minute virus of mouse (MVM), determine the species and tissue tropism, respectively.28, 29, 30, 31, 32 Similarly, the amino-acid sequence of H-1 and KRV capsid proteins differs by 20%, leading to a hypothesis that the H-1 virus and KRV would display different tropism patterns with regard to the infection in cell lines. Because rodent cells are natural hosts to the H-1 virus and KRV, we found that NRK cells are vulnerable to H-1 and KRV infection, as expected (Figure 1a). Interestingly, we found that human cervical cancer HeLa cells are also susceptible to the H-1 virus, but resist KRV infection (Figure 1a).
To test the effect of the 20% difference in primary structure of H-1 and KRV capsid proteins on the tropism displayed by the pathogens, we generated chimeric H-1 viruses, whose genome was replaced with the KRV genome, using the pSR19 vector (Figure 1b). After construction of chimeric H-1 plasmids with common restriction enzyme sites, we confirmed their recombinant sequences by DNA sequencing. Chimeric viruses were produced by transfecting NRK cells with the chimeric H-1 plasmids, and the harvested viruses were amplified for subsequent experiments.
We infected the NRK and HeLa cells with the chimeric viruses (CH1–5), and the parent KRV and H-1 viruses, and observed for cytotoxicity over 72 h using a light microscopy. As the CH1 virus carries the KRV gene fragment digested with EcoRI and HpaI (both the whole VP1-specific region and VP2), we expected the CH1 virus to exhibit behavior similar to the parent KRV. As seen in Figure 1a, CH1 virus replicated in NRK cells, but not in the HeLa cells, which matches the infection pattern of KRV. The CH2 virus, bearing the KRV gene fragment and digested with StuI and HpaI (expressing a partial VP1-specific region and VP2), induced cytotoxicity in NRK cells but not in the HeLa cells, which mimic the phenotype of KRV infection (Figure 1a). The CH3 virus on the other hand, expressing a KRV gene fragment digested with HindIII and HpaI (displaying a shorter VP1-specific region and VP2), showed a diminished NRK cell viability, but did not significantly affect the HeLa cells (Figure 1a). These results indicate that the whole VP2 domain of the KRV capsid protein is necessary for KRV-specific tropism.
We also constructed a CH4 virus, carrying the N terminus of KRV VP2, and a CH5 virus carrying the C terminus of KRV VP2 (Figure 1b). Surprisingly, we found that the CH4 and CH5 viruses induced cytotoxicity in both NRK and HeLa cells, resembling H-1 viral tropism (Figure 1a). These results indicate that H-1-specific tropism requires at least a partial VP2 capsid domain from the H-1 virus. Our findings also suggest that the VP2 capsid domain from H-1 is dominant over that of KRV.
H-1-specific tropism determined by H-1 VP2 capsid protein is observed in other human cancer cells
As the CH4 and CH5 viruses, which possessed a partial H-1 VP2 capsid domain, displayed cytolysis in HeLa cells, whereas CH1, CH2 and CH3 viruses carrying the whole KRV VP2 capsid protein did not, we decided to test these phenomena in other human cell lines. We thus introduced the viruses to human lung cancer A549 and the pancreatic adenocarcinoma Panc-1 cells. A549 and Panc-1 cells were infected with chimeric viruses (CH1–5), and the parent KRV and H-1 viruses. The cells were observed and counted by trypan blue exclusion up to 72 h after infection. We discovered that A549 and Panc-1 cells exhibited cytolysis when infected with H-1, CH4 and CH5 viruses, and were resistant to infection by KRV, CH1, CH2 and CH3 viruses (Figure 2). We also observed that the A549 and Panc-1 cells infected with H-1, CH4 and CH5 viruses undergo apoptosis owing to PARP (poly-ADP ribose polymerase) cleavage (Figure 2). These results confirm that H-1-specific tropism requires at least a partial H-1 VP2 capsid domain, and overwhelms KRV tropism.
H-1-specific tropism on HeLa cells results from amplification of virus
To test whether the cytopathic effect of H-1, CH4 and CH5 viruses on HeLa cells could be attributed to virus amplification, we examined H-1 protein levels in the cell lysates from HeLa cells infected with KRV, H-1 and CH1–5 viruses. Initially, we prepared rabbit polyclonal H-1 VP2 antibodies and confirmed their cross-reaction with the VP2 domain of KRV (which shares 80% homology with the H-1 VP2 domain). HeLa cells were infected with the parent KRV and H-1 viruses, and the five chimeric viruses. We then harvested the cells at 48 and 72 h after infection, to compare the extent of virus-directed translation. The cell lysates were prepared and separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the amount of capsid proteins was detected by western blot. We observed the VP2 domains of H-1, CH4 and CH5 viruses in the HeLa cell lysates, whereas the VP2 domains of KRV, CH1, CH2 and CH3 viruses were found to be absent (Figure 3a). However, the VP2 protein of KRV, CH1, CH2 and CH3 viruses were detected in the NRK cells (Figure 3b). These results indicate that the cytopathic effect of H-1, CH4 and CH5 viruses on HeLa cells could be attributed to viral propagation, and consequently viral protein synthesis.
Early stages of viral infection are critical for KRV- and H-1-specific tropism
To elaborate on the mechanism of KRV- and H-1-specific tropism, we analyzed the elements of the viral life cycle, such as viral entry into the host, viral transcription and viral DNA replication. We first measured the DNA concentration of viral genome from the virus stocks, and equalized the quantity of viral genomic DNA across our stocks. After 12 h of infection by parental KRV and H-1 viruses, and the five chimeric viruses, HeLa cells were harvested to compare the rates of viral transcription. The total RNAs were isolated from the infected HeLa cells and subjected to quantitative RT-PCR following cDNA synthesis. We discovered that HeLa cells infected with H-1, CH4 and CH5 viruses exhibited much higher levels of NS1 transcripts than cells infected with KRV, CH1, CH2 and CH3 viruses (Figure 4a). The result indicates that viruses (H-1, CH4 and CH5) carrying at least the H-1 VP2 domain preferentially synthesize their RNAs, compared with those viruses (KRV, CH1, CH2 and CH3) expressing the VP2 domain of KRV, in HeLa cells.
The viral DNA from HeLa cells treated with chimeric viruses and parental KRV and H-1 viruses were isolated 24 h after infection using a Viral DNA Purification Kit (Qiagen). We performed quantitative PCR to compare the rates of DNA replication between the viruses. We observed that HeLa cells infected with CH4, CH5 and H-1 viruses exhibit higher levels of NS1 DNA compared with the cells infected with KRV, CH1, CH2 and CH3 viruses (Figure 4b). This result also indicates that viruses expressing the VP2 domain of H-1 preferentially synthesize their DNA, compared with the viruses possessing the VP2 domain of KRV, in HeLa cells.
We further examined an earlier stage of viral infection in HeLa cells infected with the chimeric viruses (CH1–5), and the parental KRV and H-1 viruses. The virus-infected HeLa cells were harvested 1 h after infection to compare the steps of viral entry into the host. Viral genomic DNA was measured using quantitative PCR, 1 h after infection. We observed that HeLa cells infected with CH4, CH5 and H-1 viruses exhibit much higher levels of NS1 DNA compared with cells infected with KRV, CH1, CH2 and CH3 viruses (Figure 4b). Taken together, these results suggested that the H-1 VP2 domain determines H-1-specific tropism at an early stage of parvovirus infection.
Variable region 0 and 2 in H-1-VP2 capsid domain protrudes as compared with those seen on KRV VP2 domains
A previous study reported the presence of nine variable region (VR)s in the H-1-VP2 protein, as compared with that of other parvoviruses, such as MVM, CPV, FPV and PPV, by crystal structure analysis.8 Previous studies have also suggested that the VRs of VP2 protein from parvoviruses are involved in host cell interaction.33, 34 Based on these reports, we compared the VP2 structure between H-1 and KRV to explain the differential tropism, using SWISS modeling.26 As seen in Figure 5a, we observed that VR0 and VR2 regions from the H-1 VP2 capsid protein protrude outward, as compared with those from the KRV VP2 capsid protein. Our conclusions were supported by the alignment of the modeled VP2 capsid proteins from the two parvoviruses. VR0 and VR2 from the H-1 VP2 capsid protein contained 4 and 2 additional amino-acid residues, respectively, as compared with those from the KRV VP2 protein (Figure 5b). This result might explain the parental H-1 tropism displayed by the CH4 virus (expressing VR2 from the H-1 VP2 protein) and the CH5 chimera virus (possessing the VR0 from H-1 VP2 protein). Taken together, we suggest that VR0 and VR2 might be involved in H-1-specific infectivity to human cancer cells.
Discussion
Parvovirus infection is dependent on the S phase of host cell cycle, due to the limited genomic information of the virus. Although nondividing cells are not susceptible to these viruses, cancer cells with unlimited proliferation ability offer favorable circumstances for viral propagation.31, 35 In particular, rodent parvoviruses do not induce significant clinical symptoms in humans; therefore, the H-1 virus, among rodent parvoviruses, has been used as a virotherapeutic agent.15 A phase I clinical trial of H-1 virus therapy for brain tumor treatment is currently underway in Germany.4
In this study, we observed that H-1 virus induces cytotoxic effects in HeLa, A549 and Panc-1 cells, whereas the KRV does not, despite an 80% sequence similarity between the two viruses. We have observed that a major capsid protein of VP2 domain determines KRV and H-1 viral tropism. Our results have thus far been consistent with the observations of previous studies; for example, one study determined the MVM subtypes (lymphotropic and fibrotropic forms) based on the two amino-acid residues on the MVM capsid protein.36 Another study investigating the different tropisms exhibited by CPV and FPV demonstrated that a sequence within the gene coding for the VP1 and VP2 structural proteins differentiated the host range of these viruses, despite the near identity between the viral gene sequences.28, 29, 30 Yet, another report showed that the introduction of VP2 capsid protein from Lu III parvovirus into fibrotropic MVM results in the recombinant MVM acquiring infectious and cytotoxic ability in human melanoma cells.37 Furthermore, a recent study reported that the VP1 unique region of human parvovirus B19 is involved in viral binding and internalization in erythroid cell lines, suggesting that VP1 of the virus can also determine viral tropism.38
A search for the explanation of the specific tropism of parvoviruses has revealed the binding properties and functional activity of the viral receptors. Examples include some globosides and α5β1-integrin for human parvovirus B19,39, 40 transferrin receptor for CPV, FPV and mink enteritis virus,41, 42 and heparin sulfate, αvβ5-integrin, and growth factor receptor for adeno-associated viruses.43, 44, 45 In addition to these individual receptors, sialic acid serves as a common attachment factor for many parvoviruses, such as MVM, adeno-associated virus 1, adeno-associated virus 4, bovine parvovirus, CPV and FPV.33 These reports indicate the involvement of more than one molecule in parvovirus entry into the host cell. Given these findings, we could imagine that VR0 from H-1 VP2 capsid protein binds to one receptor on the HeLa cells, whereas the VR2 from the same protein interacts with a different host receptor. We therefore propose that the loss of one interaction between viral capsid domain and host receptor does not necessarily diminish the infectivity of the parvovirus. The behaviors of the CH4 virus expressing the VR2 region from H-1 VP2 protein, and the CH5 virus possessing the VR0 region from the same protein observed in our study may demonstrate this point, as the expression of at least one terminus of the H-1 VP2 capsid protein appeared to be enough to retain potency of the CH4 and CH5 infection in human cancer cells.
In this study, we observed preferential DNA replication, RNA transcript and protein synthesis of H-1, CH4 and CH5 viruses compared with KRV, CH1, CH2 and CH3 viruses in HeLa cells. However, the effect of specific amino-acid residues of VR0 or VR2 regions from the H-1 VP2 capsid protein on early events of the viral life cycle, such as viral entry, endosome escape, nuclear trafficking and uncoating, remain to be investigated. This could help determine the unique tropism patterns expressed by different viruses.
Change history
30 March 2021
A Correction to this paper has been published: https://doi.org/10.1038/s41417-021-00315-7
References
Tamura K, Wakimoto H, Agarwal AS, Rabkin SD, Bhere D, Martuza RL et al. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol Ther 2013; 21: 68–77.
Beljanski V, Hiscott J . The use of oncolytic viruses to overcome lung cancer drug resistance. Curr Opin Virol 2012; 2: 629–635.
Russell SJ, Peng KW, Bell JC . Oncolytic virotherapy. Nat Biotechnol 2012; 30: 658–670.
Geletneky K, Huesing J, Rommelaere J, Schlehofer JR, Leuchs B, Dahm M et al. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer 2012; 12: 99.
Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ et al. Phase II trial of intravenous administration of Reolysin((R)) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther 2012; 20: 1998–2003.
Kicielinski KP, Chiocca EA, Yu JS, Gill GM, Coffey M, Markert JM . Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther 2014; 22: 1056–1062.
Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19: 329–336.
Halder S, Nam HJ, Govindasamy L, Vogel M, Dinsart C, Salome N et al. Structural characterization of H-1 parvovirus: comparison of infectious virions to empty capsids. J Virol 2013; 87: 5128–5140.
Becerra SP, Koczot F, Fabisch P, Rose JA . Synthesis of adeno-associated virus structural proteins requires both alternative mRNA splicing and alternative initiations from a single transcript. J Virol 1988; 62: 2745–2754.
Cotmore SF, Tattersall P . The autonomously replicating parvoviruses of vertebrates. Adv Virus Res 1987; 33: 91–174.
Van Pachterbeke C, Tuynder M, Cosyn JP, Lespagnard L, Larsimont D, Rommelaere J . Parvovirus H-1 inhibits growth of short-term tumor-derived but not normal mammary tissue cultures. Int J Cancer 1993; 55: 672–677.
Van Pachterbeke C, Tuynder M, Brandenburger A, Leclercq G, Borras M, Rommelaere J . Varying sensitivity of human mammary carcinoma cells to the toxic effect of parvovirus H-1. Eur J Cancer 1997; 33: 1648–1653.
Rayet B, Lopez-Guerrero JA, Rommelaere J, Dinsart C . Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway. J Virol 1998; 72: 8893–8903.
Di Piazza M, Mader C, Geletneky K, Herrero YCM, Weber E, Schlehofer J et al. Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J Virol 2007; 81: 4186–4198.
Moehler M, Sieben M, Roth S, Springsguth F, Leuchs B, Zeidler M et al. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1. BMC Cancer 2011; 11: 464.
Li J, Werner E, Hergenhahn M, Poirey R, Luo Z, Rommelaere J et al. Expression profiling of human hepatoma cells reveals global repression of genes involved in cell proliferation, growth, and apoptosis upon infection with parvovirus H-1. J Virol 2005; 79: 2274–2286.
Lacroix J, Schlund F, Leuchs B, Adolph K, Sturm D, Bender S et al. Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis. Int J Cancer 2014; 134: 703–716.
Malerba M, Daeffler L, Rommelaere J, Iggo RD . Replicating parvoviruses that target colon cancer cells. J Virol 2003; 77: 6683–6691.
Wang YY, Liu J, Zheng Q, Ran ZH, Salome N, Vogel M et al. Effect of the parvovirus H-1 non-structural protein NS1 on the tumorigenicity of human gastric cancer cells. J Dig Dis 2012; 13: 366–373.
Gunther M, Prigent-Tiravy S, Wicker R . Kilham rat virus DNA replication in subcellular fractions. J Gen Virol 1984; 65 (Part 11): 2021–2031.
Guberski DL, Thomas VA, Shek WR, Like AA, Handler ES, Rossini AA et al. Induction of type I diabetes by Kilham's rat virus in diabetes-resistant BB/Wor rats. Science 1991; 254: 1010–1013.
Chung YH, Jun HS, Son M, Bao M, Bae HY, Kang Y et al. Cellular and molecular mechanism for Kilham rat virus-induced autoimmune diabetes in DR-BB rats. J Immunol 2000; 165: 2866–2876.
Zipris D, Hillebrands JL, Welsh RM, Rozing J, Xie JX, Mordes JP et al. Infections that induce autoimmune diabetes in BBDR rats modulate CD4+CD25+ T cell populations. J Immunol 2003; 170: 3592–3602.
Gunther M, May P . Isolation and structural characterization of monomeric and dimeric forms of replicative intermediates of Kilham rat virus DNA. J Virol 1976; 20: 86–95.
Rhode SL III, Paradiso PR . Parvovirus genome: nucleotide sequence of H-1 and mapping of its genes by hybrid-arrested translation. J Virol 1983; 45: 173–184.
Schwede T, Kopp J, Guex N, Peitsch MC . SWISS-MODEL: Aan automated protein homology-modeling server. Nucleic Acids Res 2003; 31: 3381–3385.
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC et al. UCSF chimera—a visualization system for exploratory research and analysis. J Comput Chem 2004; 25: 1605–1612.
Truyen U, Parrish CR . Canine and feline host ranges of canine parvovirus and feline panleukopenia virus: distinct host cell tropisms of each virus in vitro and in vivo. J Virol 1992; 66: 5399–5408.
Truyen U, Agbandje M, Parrish CR . Characterization of the feline host range and a specific epitope of feline panleukopenia virus. Virology 1994; 200: 494–503.
Parker JS, Parrish CR . Canine parvovirus host range is determined by the specific conformation of an additional region of the capsid. J Virol 1997; 71: 9214–9222.
Spalholz BA, Tattersall P . Interaction of minute virus of mice with differentiated cells: strain-dependent target cell specificity is mediated by intracellular factors. J Virol 1983; 46: 937–943.
Kimsey PB, Engers HD, Hirt B, Jongeneel CV . Pathogenicity of fibroblast- and lymphocyte-specific variants of minute virus of mice. J Virol 1986; 59: 8–13.
Lopez-Bueno A, Rubio MP, Bryant N, McKenna R, Agbandje-McKenna M, Almendral JM . Host-selected amino acid changes at the sialic acid binding pocket of the parvovirus capsid modulate cell binding affinity and determine virulence. J Virol 2006; 80: 1563–1573.
Barbis DP, Chang SF, Parrish CR . Mutations adjacent to the dimple of the canine parvovirus capsid structure affect sialic acid binding. Virology 1992; 191: 301–308.
Nemunaitis J . Oncolytic viruses. Invest New Drugs 1999; 17: 375–386.
Ball-Goodrich LJ, Tattersall P . Two amino acid substitutions within the capsid are coordinately required for acquisition of fibrotropism by the lymphotropic strain of minute virus of mice. J Virol 1992; 66: 3415–3423.
Paglino J, Tattersall P . The parvoviral capsid controls an intracellular phase of infection essential for efficient killing of stepwise-transformed human fibroblasts. Virology 2011; 416: 32–41.
Leisi R, Ruprecht N, Kempf C, Ros C . Parvovirus B19 uptake is a highly selective process controlled by VP1u, a novel determinant of viral tropism. J Virol 2013; 87: 13161–13167.
Weigel-Kelley KA, Yoder MC, Srivastava A . Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood 2003; 102: 3927–3933.
Brown KE, Anderson SM, Young NS . Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993; 262: 114–117.
Parker JS, Murphy WJ, Wang D, O'Brien SJ, Parrish CR . Canine and feline parvoviruses can use human or feline transferrin receptors to bind, enter, and infect cells. J Virol 2001; 75: 3896–3902.
Park GS, Best SM, Bloom ME . Two mink parvoviruses use different cellular receptors for entry into CRFK cells. Virology 2005; 340: 1–9.
Kashiwakura Y, Tamayose K, Iwabuchi K, Hirai Y, Shimada T, Matsumoto K et al. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol 2005; 79: 609–614.
Summerford C, Samulski RJ . Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438–1445.
Summerford C, Bartlett JS, Samulski RJ . AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999; 5: 78–82.
Acknowledgements
We are grateful to Charles C Chung for proofreading the manuscript. This study was supported by a grant from the Basic Research Program (NRF-2012R A1A2038385) of the National Research Foundation, funded by the Korean government.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
About this article
Cite this article
Cho, IR., Kaowinn, S., Song, J. et al. RETRACTED ARTICLE: VP2 capsid domain of the H-1 parvovirus determines susceptibility of human cancer cells to H-1 viral infection. Cancer Gene Ther 22, 271–277 (2015). https://doi.org/10.1038/cgt.2015.17
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2015.17